Dopamine beta-hydroxylase and beta 2-microglobulin in cerebrospinal fluid: early markers in Parkinson’s disease?

  • T. Nagastu
  • M. Mogi
  • M. Harada
  • K. Kojima
Part of the New Vistas in Drug Research book series (DRUG RESEARCH, volume 1)


Dopamine beta-hydroxylase (DBH) activity, DBH protein, and beta 2-microglobulin (B 2-MG), the light chain of the class 1 major histocompatibility complex (MHC), were found to be significantly reduced in cerebrospinal fluid (CSF) from parkinsonian patients. A significantly positive correlation was observed between DBH activity and DBH protein or B 2-MG. The results suggest a probable link between the changes in the immune system and those in the noradrenergic neurons in Parkinson’s disease. It remains to be examined whether DBH or B 2-MG in CSF could be an early marker in Parkinson’s disease.


Major Histocompatibility Complex Tyrosine Hydroxylase Parkinsonian Patient Dipeptidyl Peptidase Human Cerebrospinal Fluid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bradford MM (1976) Rapid and sensitive method for quantitation of microgram quantities of proteins utilizing the principle of protein-dye binding. Anal Biochem 72: 248–254PubMedCrossRefGoogle Scholar
  2. Gorevic PD, Munoz PC, Casey TT, DiRaimondo DR, Stone WJ, Prelli FC, Rodrigues MM, Poulik MD, Frangione B (1986) Polymerization of intact beta 2-microglobulin in tissue causes amyloidosis in patients with chronic hemodialyses. Proc Natl Acad Sci USA 83: 7908–7912PubMedCrossRefGoogle Scholar
  3. Hagihara M, Nagatsu T (1987) Post-proline cleaving enzyme in human cerebrospinal fluid from control patients and parkinsonian patients. Biochem Med Metabol Biol 38: 387–391CrossRefGoogle Scholar
  4. Hagihara M, Mihara R, Togari A, Nagatsu T (1987) Dipeptidyl-aminopeptidase II in human cerebrospinal fluid: changes in patients with Parkinson’s disease. Biochem Med Metabol Biol 37: 360–365CrossRefGoogle Scholar
  5. Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17: 427–442PubMedGoogle Scholar
  6. Lovenberg W, Levine RA, Robinson DS, Ebert M, Williams AC, Calne DB (1979) Hydroxylase cofactor activity in cerebrospinal fluid of normal subjects and patients with Parkinson’s disease. Science 204: 624–626PubMedCrossRefGoogle Scholar
  7. Matsui H, Kato T, Yamamoto C, Fujita K, Nagatsu T (1981) Highly sensitive assay for dopamine-β-hydroxylase activity in human cerebrospinal fluid by high-performance liquid chromatography-electrochemical detection: properties of the enzyme. J Neurochem 37: 289–296PubMedCrossRefGoogle Scholar
  8. Mogi M, Kojima K, Nagatsu T (1984) Detection of inactive or less active forms of tyrosine hydroxylase in human adrenals by a sandwich enzyme immunoassay. Anal Biochem 138: 125–132PubMedCrossRefGoogle Scholar
  9. Mogi M, Harada M, Kojima K, Inagaki H, Kondo T, Narabayashi H, Arai T, Teradaira R, Fujita K, Kiuchi K, Nagatsu T (1988) Sandwich enzyme immunoassay of dopamine-I3-hydroxylase in cerebrospinal fluid from controls and parkinsonian patients. Neurochem Int 12: 187–191PubMedCrossRefGoogle Scholar
  10. Mogi M, Harada M, Kojima K, Adachi T, Narabayashi H, Fujita K, Naoi M, Nagatsu T (1989) Beta 2-microglobulin decrease in cerebrospinal fluid from parkinsonian patients. Neurosci Lett 104: 241–246PubMedCrossRefGoogle Scholar
  11. Nagatsu T (1977) Dopamine-(3-hydroxylase in blood and cerebrospinal fluid. Trends Biochem Sci 2: 217–219CrossRefGoogle Scholar
  12. Nagatsu T, Kato T, Numata (Sudo) Y, Ikuta K, Sano M, Nagatsu I, Kondo Y, Inagaki S, Ikuta R, Hod A, Narabayashi H (1977) Phenylethanolamine N-methyltransferase and other enzymes of catecholamine metabolism in human brain. Clin Chim Acta 75: 221–232PubMedCrossRefGoogle Scholar
  13. Nagatsu T, Yamaguchi T, Kato T, Sugimoto T, Matsuzaki S, Akino M, Nagatsu I, Iizuka R, Narabayashi H (1981) Biopterin in human brain and urine from control and parkinsonian patients: application of a new radioimmunoassay. Clin Chim Acta 109: 305–311PubMedCrossRefGoogle Scholar
  14. Nagatsu T, Wakui Y, Kato T, Fujita K, Kondo T, Yokochi F, Narabayashi H (1982) Dopamine beta-hydroxylase activity in cerebrospinal fluid of parkinsonian patients. Biomed Res 3: 95–98Google Scholar
  15. Nagatsu T, Yamazaki T, Rahman MK, Trocewicz J, Oka K, Hirata Y, Nagatsu I, Narabayashi H, Kondo T, Iizuka R (1984) Catecholaminerelated enzymes and the biopterin cofactor in Parkinson’s disease and related extra-pyramidal diseases. Adv Neurol 40: 467–481PubMedGoogle Scholar
  16. Ruberg M, Rieger F, Villageois A, Bonnet AM, Azid Y (1986) Acetylcholinesterase and butyrylcholinesterase in frontal cortex and cerebrospinal fluid of demented and non-demented patients with Parkinson’s disease. Brain Res 362: 83–91PubMedCrossRefGoogle Scholar
  17. Starmans JJP, Vos J, Van Der Helm HJ (1977) The beta 2-microglobulin content of the cerebrospinal fluid in neurological disease. J Neurol Sci 33: 45–49PubMedCrossRefGoogle Scholar
  18. Suzuki H, Yata J, Kojima K, Nagatsu T (1985) Simple and sensitive assay of dopamine-β-hydroxylase in human cerebrospinal fluid by high-performance liquid chromatography with electrochemical detection. J Chromatogr 341: 176–181PubMedCrossRefGoogle Scholar
  19. Wibell L, Evrin PE, Berggard I (1973) Serum beta 2-microglobulin in renal disease. Nephron 10: 320–331PubMedCrossRefGoogle Scholar
  20. Yamaguchi T, Nagatsu T, Sugimoto T, Matsuura S, Kondo T, Iizuka R, Narabayashi H (1983) Effects of tyrosine administration on serum biopterin in normal controls and patients with Parkinson’s disease. Science 219: 75–77PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag/Wien 1990

Authors and Affiliations

  • T. Nagastu
    • 1
  • M. Mogi
    • 2
  • M. Harada
    • 2
  • K. Kojima
    • 3
  1. 1.Department of BiochemistryNagoya University School of MedicineNagoyaJapan
  2. 2.Department of Oral BiochemistryMatsumoto Dental CollegeShiojiriJapan
  3. 3.Hatano Research InstituteFood and Drug Safety CenterHatanoJapan

Personalised recommendations